What is testicular atrophy?
Testicular atrophy is a reduction in testicle size that occurs during testosterone replacement therapy due to suppressed production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
During testosterone replacement therapy, the testes often shrink because external testosterone suppresses the pituitary gland's release of LH and FSH, the hormones that normally trigger testicular function and sperm production. When these signals diminish, the testes downregulate and lose volume. This atrophy is a common physiological response in men receiving TRT, particularly those on larger doses or longer treatment durations.
The degree of shrinkage varies by individual and depends on factors like baseline testosterone levels, dosing protocol, and duration of therapy. While testicular atrophy does not always impair sexual function or require intervention, many patients seek to minimize it for fertility preservation or to maintain testicular health long-term.
Two medications can help offset atrophy during TRT. Human chorionic gonadotropin (hCG) mimics LH signaling and directly stimulates the testes to maintain size and sperm production. Gonadorelin (a GnRH agonist) prompts the pituitary to release endogenous LH and FSH, restoring the body's native hormonal signaling. Both adjuncts help preserve or restore testicular volume while a patient continues testosterone therapy. TRT clinics in Florida typically assess atrophy risk during intake and offer these medications as part of a comprehensive protocol. For a list of hormone therapy providers, consult the directory.